nodes	percent_of_prediction	percent_of_DWPC	metapath
Lithium—IMPA2—islet of Langerhans—pancreatic cancer	0.0166	0.206	CbGeAlD
Lithium—GSK3A—islet of Langerhans—pancreatic cancer	0.0141	0.176	CbGeAlD
Lithium—IMPA2—pancreas—pancreatic cancer	0.0116	0.145	CbGeAlD
Lithium—IMPA2—digestive system—pancreatic cancer	0.00995	0.124	CbGeAlD
Lithium—GSK3A—pancreas—pancreatic cancer	0.00994	0.123	CbGeAlD
Lithium—GSK3B—digestive system—pancreatic cancer	0.00976	0.121	CbGeAlD
Lithium—GSK3A—digestive system—pancreatic cancer	0.00849	0.105	CbGeAlD
Lithium—Salivary hypersecretion—Epirubicin—pancreatic cancer	0.000808	0.00267	CcSEcCtD
Lithium—Arthralgia—Sunitinib—pancreatic cancer	0.000806	0.00267	CcSEcCtD
Lithium—Arrhythmia—Irinotecan—pancreatic cancer	0.0008	0.00265	CcSEcCtD
Lithium—Dyspepsia—Tamoxifen—pancreatic cancer	0.000794	0.00263	CcSEcCtD
Lithium—Alopecia—Irinotecan—pancreatic cancer	0.000791	0.00262	CcSEcCtD
Lithium—Dry mouth—Sunitinib—pancreatic cancer	0.000788	0.00261	CcSEcCtD
Lithium—Dyspepsia—Erlotinib—pancreatic cancer	0.000785	0.0026	CcSEcCtD
Lithium—Decreased appetite—Tamoxifen—pancreatic cancer	0.000784	0.0026	CcSEcCtD
Lithium—Coordination abnormal—Doxorubicin—pancreatic cancer	0.000784	0.00259	CcSEcCtD
Lithium—Arrhythmia—Gemcitabine—pancreatic cancer	0.000779	0.00258	CcSEcCtD
Lithium—Fatigue—Tamoxifen—pancreatic cancer	0.000778	0.00257	CcSEcCtD
Lithium—Decreased appetite—Erlotinib—pancreatic cancer	0.000776	0.00257	CcSEcCtD
Lithium—Oedema—Sunitinib—pancreatic cancer	0.000772	0.00256	CcSEcCtD
Lithium—Alopecia—Gemcitabine—pancreatic cancer	0.000771	0.00255	CcSEcCtD
Lithium—Fatigue—Erlotinib—pancreatic cancer	0.000769	0.00255	CcSEcCtD
Lithium—Flatulence—Irinotecan—pancreatic cancer	0.000768	0.00254	CcSEcCtD
Lithium—Arrhythmia—Fluorouracil—pancreatic cancer	0.000766	0.00254	CcSEcCtD
Lithium—Shock—Sunitinib—pancreatic cancer	0.00076	0.00252	CcSEcCtD
Lithium—Coma—Epirubicin—pancreatic cancer	0.00076	0.00252	CcSEcCtD
Lithium—Alopecia—Fluorouracil—pancreatic cancer	0.000758	0.00251	CcSEcCtD
Lithium—Salivary hypersecretion—Doxorubicin—pancreatic cancer	0.000747	0.00247	CcSEcCtD
Lithium—Gastrointestinal pain—Tamoxifen—pancreatic cancer	0.000738	0.00244	CcSEcCtD
Lithium—Anorexia—Sunitinib—pancreatic cancer	0.000736	0.00244	CcSEcCtD
Lithium—Gastrointestinal pain—Erlotinib—pancreatic cancer	0.00073	0.00242	CcSEcCtD
Lithium—Hypertonia—Epirubicin—pancreatic cancer	0.000729	0.00241	CcSEcCtD
Lithium—Abdominal pain—Tamoxifen—pancreatic cancer	0.000713	0.00236	CcSEcCtD
Lithium—Abdominal pain—Erlotinib—pancreatic cancer	0.000705	0.00234	CcSEcCtD
Lithium—Body temperature increased—Erlotinib—pancreatic cancer	0.000705	0.00234	CcSEcCtD
Lithium—Weight increased—Docetaxel—pancreatic cancer	0.000704	0.00233	CcSEcCtD
Lithium—Musculoskeletal discomfort—Sunitinib—pancreatic cancer	0.000704	0.00233	CcSEcCtD
Lithium—Vision blurred—Fluorouracil—pancreatic cancer	0.000704	0.00233	CcSEcCtD
Lithium—Coma—Doxorubicin—pancreatic cancer	0.000703	0.00233	CcSEcCtD
Lithium—Vertigo—Irinotecan—pancreatic cancer	0.0007	0.00232	CcSEcCtD
Lithium—Weight decreased—Docetaxel—pancreatic cancer	0.0007	0.00232	CcSEcCtD
Lithium—Syncope—Irinotecan—pancreatic cancer	0.000699	0.00232	CcSEcCtD
Lithium—Loss of consciousness—Irinotecan—pancreatic cancer	0.000685	0.00227	CcSEcCtD
Lithium—Dyspepsia—Sunitinib—pancreatic cancer	0.00068	0.00225	CcSEcCtD
Lithium—Hypertonia—Doxorubicin—pancreatic cancer	0.000674	0.00223	CcSEcCtD
Lithium—Decreased appetite—Sunitinib—pancreatic cancer	0.000672	0.00222	CcSEcCtD
Lithium—Fatigue—Sunitinib—pancreatic cancer	0.000666	0.00221	CcSEcCtD
Lithium—Discomfort—Irinotecan—pancreatic cancer	0.000656	0.00217	CcSEcCtD
Lithium—Asthenia—Tamoxifen—pancreatic cancer	0.000647	0.00214	CcSEcCtD
Lithium—Convulsion—Fluorouracil—pancreatic cancer	0.000647	0.00214	CcSEcCtD
Lithium—Arthralgia—Gemcitabine—pancreatic cancer	0.000647	0.00214	CcSEcCtD
Lithium—Confusional state—Irinotecan—pancreatic cancer	0.000642	0.00212	CcSEcCtD
Lithium—Asthenia—Erlotinib—pancreatic cancer	0.00064	0.00212	CcSEcCtD
Lithium—Discomfort—Gemcitabine—pancreatic cancer	0.000639	0.00212	CcSEcCtD
Lithium—Oedema—Irinotecan—pancreatic cancer	0.000636	0.00211	CcSEcCtD
Lithium—Gastrointestinal pain—Sunitinib—pancreatic cancer	0.000632	0.00209	CcSEcCtD
Lithium—Discomfort—Fluorouracil—pancreatic cancer	0.000628	0.00208	CcSEcCtD
Lithium—Shock—Irinotecan—pancreatic cancer	0.000626	0.00207	CcSEcCtD
Lithium—Oedema—Gemcitabine—pancreatic cancer	0.00062	0.00205	CcSEcCtD
Lithium—Diarrhoea—Tamoxifen—pancreatic cancer	0.000617	0.00204	CcSEcCtD
Lithium—Lethargy—Epirubicin—pancreatic cancer	0.000616	0.00204	CcSEcCtD
Lithium—Confusional state—Fluorouracil—pancreatic cancer	0.000614	0.00203	CcSEcCtD
Lithium—Body temperature increased—Sunitinib—pancreatic cancer	0.000611	0.00202	CcSEcCtD
Lithium—Abdominal pain—Sunitinib—pancreatic cancer	0.000611	0.00202	CcSEcCtD
Lithium—Diarrhoea—Erlotinib—pancreatic cancer	0.000611	0.00202	CcSEcCtD
Lithium—Oedema—Fluorouracil—pancreatic cancer	0.000609	0.00202	CcSEcCtD
Lithium—Anorexia—Irinotecan—pancreatic cancer	0.000607	0.00201	CcSEcCtD
Lithium—Dizziness—Tamoxifen—pancreatic cancer	0.000596	0.00197	CcSEcCtD
Lithium—Hypotension—Irinotecan—pancreatic cancer	0.000595	0.00197	CcSEcCtD
Lithium—Anorexia—Gemcitabine—pancreatic cancer	0.000591	0.00196	CcSEcCtD
Lithium—Dizziness—Erlotinib—pancreatic cancer	0.00059	0.00195	CcSEcCtD
Lithium—Anorexia—Fluorouracil—pancreatic cancer	0.000581	0.00192	CcSEcCtD
Lithium—Hypotension—Gemcitabine—pancreatic cancer	0.000579	0.00192	CcSEcCtD
Lithium—Vomiting—Tamoxifen—pancreatic cancer	0.000573	0.0019	CcSEcCtD
Lithium—Lethargy—Doxorubicin—pancreatic cancer	0.00057	0.00189	CcSEcCtD
Lithium—Hypotension—Fluorouracil—pancreatic cancer	0.000569	0.00189	CcSEcCtD
Lithium—Rash—Tamoxifen—pancreatic cancer	0.000569	0.00188	CcSEcCtD
Lithium—Dermatitis—Tamoxifen—pancreatic cancer	0.000568	0.00188	CcSEcCtD
Lithium—Ataxia—Epirubicin—pancreatic cancer	0.000568	0.00188	CcSEcCtD
Lithium—Vomiting—Erlotinib—pancreatic cancer	0.000567	0.00188	CcSEcCtD
Lithium—Somnolence—Irinotecan—pancreatic cancer	0.000566	0.00187	CcSEcCtD
Lithium—Headache—Tamoxifen—pancreatic cancer	0.000565	0.00187	CcSEcCtD
Lithium—Musculoskeletal discomfort—Gemcitabine—pancreatic cancer	0.000565	0.00187	CcSEcCtD
Lithium—Rash—Erlotinib—pancreatic cancer	0.000563	0.00186	CcSEcCtD
Lithium—Dermatitis—Erlotinib—pancreatic cancer	0.000562	0.00186	CcSEcCtD
Lithium—Dehydration—Epirubicin—pancreatic cancer	0.000561	0.00186	CcSEcCtD
Lithium—Dyspepsia—Irinotecan—pancreatic cancer	0.00056	0.00185	CcSEcCtD
Lithium—Headache—Erlotinib—pancreatic cancer	0.000559	0.00185	CcSEcCtD
Lithium—Musculoskeletal discomfort—Fluorouracil—pancreatic cancer	0.000555	0.00184	CcSEcCtD
Lithium—Asthenia—Sunitinib—pancreatic cancer	0.000554	0.00184	CcSEcCtD
Lithium—Dry skin—Epirubicin—pancreatic cancer	0.000553	0.00183	CcSEcCtD
Lithium—Decreased appetite—Irinotecan—pancreatic cancer	0.000553	0.00183	CcSEcCtD
Lithium—Arrhythmia—Docetaxel—pancreatic cancer	0.000553	0.00183	CcSEcCtD
Lithium—Somnolence—Gemcitabine—pancreatic cancer	0.000551	0.00182	CcSEcCtD
Lithium—Fatigue—Irinotecan—pancreatic cancer	0.000549	0.00182	CcSEcCtD
Lithium—Alopecia—Docetaxel—pancreatic cancer	0.000547	0.00181	CcSEcCtD
Lithium—Somnolence—Fluorouracil—pancreatic cancer	0.000542	0.00179	CcSEcCtD
Lithium—Decreased appetite—Gemcitabine—pancreatic cancer	0.000539	0.00178	CcSEcCtD
Lithium—Dyspepsia—Fluorouracil—pancreatic cancer	0.000536	0.00178	CcSEcCtD
Lithium—Nausea—Tamoxifen—pancreatic cancer	0.000536	0.00177	CcSEcCtD
Lithium—Fatigue—Gemcitabine—pancreatic cancer	0.000534	0.00177	CcSEcCtD
Lithium—Gastritis—Epirubicin—pancreatic cancer	0.000534	0.00177	CcSEcCtD
Lithium—Muscular weakness—Epirubicin—pancreatic cancer	0.000532	0.00176	CcSEcCtD
Lithium—Nausea—Erlotinib—pancreatic cancer	0.00053	0.00176	CcSEcCtD
Lithium—Decreased appetite—Fluorouracil—pancreatic cancer	0.00053	0.00175	CcSEcCtD
Lithium—Diarrhoea—Sunitinib—pancreatic cancer	0.000529	0.00175	CcSEcCtD
Lithium—Dysgeusia—Docetaxel—pancreatic cancer	0.000528	0.00175	CcSEcCtD
Lithium—Ataxia—Doxorubicin—pancreatic cancer	0.000525	0.00174	CcSEcCtD
Lithium—Feeling abnormal—Irinotecan—pancreatic cancer	0.000524	0.00174	CcSEcCtD
Lithium—Gastrointestinal pain—Irinotecan—pancreatic cancer	0.00052	0.00172	CcSEcCtD
Lithium—Dehydration—Doxorubicin—pancreatic cancer	0.000519	0.00172	CcSEcCtD
Lithium—Dry skin—Doxorubicin—pancreatic cancer	0.000512	0.0017	CcSEcCtD
Lithium—Dizziness—Sunitinib—pancreatic cancer	0.000511	0.00169	CcSEcCtD
Lithium—Feeling abnormal—Gemcitabine—pancreatic cancer	0.000511	0.00169	CcSEcCtD
Lithium—Abdominal pain—Irinotecan—pancreatic cancer	0.000503	0.00167	CcSEcCtD
Lithium—Body temperature increased—Irinotecan—pancreatic cancer	0.000503	0.00167	CcSEcCtD
Lithium—Feeling abnormal—Fluorouracil—pancreatic cancer	0.000502	0.00166	CcSEcCtD
Lithium—Gastritis—Doxorubicin—pancreatic cancer	0.000494	0.00164	CcSEcCtD
Lithium—Muscular weakness—Doxorubicin—pancreatic cancer	0.000493	0.00163	CcSEcCtD
Lithium—Vomiting—Sunitinib—pancreatic cancer	0.000491	0.00163	CcSEcCtD
Lithium—Body temperature increased—Gemcitabine—pancreatic cancer	0.00049	0.00162	CcSEcCtD
Lithium—Rash—Sunitinib—pancreatic cancer	0.000487	0.00161	CcSEcCtD
Lithium—Dermatitis—Sunitinib—pancreatic cancer	0.000487	0.00161	CcSEcCtD
Lithium—Headache—Sunitinib—pancreatic cancer	0.000484	0.0016	CcSEcCtD
Lithium—Syncope—Docetaxel—pancreatic cancer	0.000483	0.0016	CcSEcCtD
Lithium—Body temperature increased—Fluorouracil—pancreatic cancer	0.000482	0.0016	CcSEcCtD
Lithium—Weight increased—Epirubicin—pancreatic cancer	0.000475	0.00157	CcSEcCtD
Lithium—Loss of consciousness—Docetaxel—pancreatic cancer	0.000474	0.00157	CcSEcCtD
Lithium—Weight decreased—Epirubicin—pancreatic cancer	0.000472	0.00156	CcSEcCtD
Lithium—Hyperglycaemia—Epirubicin—pancreatic cancer	0.000471	0.00156	CcSEcCtD
Lithium—Convulsion—Docetaxel—pancreatic cancer	0.000467	0.00155	CcSEcCtD
Lithium—Drowsiness—Epirubicin—pancreatic cancer	0.000465	0.00154	CcSEcCtD
Lithium—Arthralgia—Docetaxel—pancreatic cancer	0.000459	0.00152	CcSEcCtD
Lithium—Nausea—Sunitinib—pancreatic cancer	0.000459	0.00152	CcSEcCtD
Lithium—Asthenia—Irinotecan—pancreatic cancer	0.000457	0.00151	CcSEcCtD
Lithium—Dry mouth—Docetaxel—pancreatic cancer	0.000449	0.00149	CcSEcCtD
Lithium—Asthenia—Gemcitabine—pancreatic cancer	0.000445	0.00147	CcSEcCtD
Lithium—Confusional state—Docetaxel—pancreatic cancer	0.000444	0.00147	CcSEcCtD
Lithium—Oedema—Docetaxel—pancreatic cancer	0.00044	0.00146	CcSEcCtD
Lithium—Weight increased—Doxorubicin—pancreatic cancer	0.000439	0.00145	CcSEcCtD
Lithium—Weight decreased—Doxorubicin—pancreatic cancer	0.000437	0.00145	CcSEcCtD
Lithium—Hyperglycaemia—Doxorubicin—pancreatic cancer	0.000435	0.00144	CcSEcCtD
Lithium—Diarrhoea—Irinotecan—pancreatic cancer	0.000435	0.00144	CcSEcCtD
Lithium—Shock—Docetaxel—pancreatic cancer	0.000433	0.00143	CcSEcCtD
Lithium—Drowsiness—Doxorubicin—pancreatic cancer	0.00043	0.00143	CcSEcCtD
Lithium—Bradycardia—Epirubicin—pancreatic cancer	0.000425	0.00141	CcSEcCtD
Lithium—Diarrhoea—Gemcitabine—pancreatic cancer	0.000424	0.0014	CcSEcCtD
Lithium—Dizziness—Irinotecan—pancreatic cancer	0.000421	0.00139	CcSEcCtD
Lithium—Anorexia—Docetaxel—pancreatic cancer	0.000419	0.00139	CcSEcCtD
Lithium—Diarrhoea—Fluorouracil—pancreatic cancer	0.000417	0.00138	CcSEcCtD
Lithium—Hypotension—Docetaxel—pancreatic cancer	0.000411	0.00136	CcSEcCtD
Lithium—Vomiting—Irinotecan—pancreatic cancer	0.000405	0.00134	CcSEcCtD
Lithium—Dizziness—Fluorouracil—pancreatic cancer	0.000403	0.00133	CcSEcCtD
Lithium—Rash—Irinotecan—pancreatic cancer	0.000401	0.00133	CcSEcCtD
Lithium—Dermatitis—Irinotecan—pancreatic cancer	0.000401	0.00133	CcSEcCtD
Lithium—Musculoskeletal discomfort—Docetaxel—pancreatic cancer	0.000401	0.00133	CcSEcCtD
Lithium—Headache—Irinotecan—pancreatic cancer	0.000399	0.00132	CcSEcCtD
Lithium—Vomiting—Gemcitabine—pancreatic cancer	0.000394	0.0013	CcSEcCtD
Lithium—Bradycardia—Doxorubicin—pancreatic cancer	0.000393	0.0013	CcSEcCtD
Lithium—Somnolence—Docetaxel—pancreatic cancer	0.000391	0.00129	CcSEcCtD
Lithium—Rash—Gemcitabine—pancreatic cancer	0.000391	0.00129	CcSEcCtD
Lithium—Dermatitis—Gemcitabine—pancreatic cancer	0.00039	0.00129	CcSEcCtD
Lithium—Tinnitus—Epirubicin—pancreatic cancer	0.000389	0.00129	CcSEcCtD
Lithium—Headache—Gemcitabine—pancreatic cancer	0.000388	0.00129	CcSEcCtD
Lithium—Vomiting—Fluorouracil—pancreatic cancer	0.000387	0.00128	CcSEcCtD
Lithium—Dyspepsia—Docetaxel—pancreatic cancer	0.000387	0.00128	CcSEcCtD
Lithium—Rash—Fluorouracil—pancreatic cancer	0.000384	0.00127	CcSEcCtD
Lithium—Dermatitis—Fluorouracil—pancreatic cancer	0.000384	0.00127	CcSEcCtD
Lithium—Decreased appetite—Docetaxel—pancreatic cancer	0.000382	0.00127	CcSEcCtD
Lithium—Headache—Fluorouracil—pancreatic cancer	0.000382	0.00126	CcSEcCtD
Lithium—Fatigue—Docetaxel—pancreatic cancer	0.000379	0.00126	CcSEcCtD
Lithium—Nausea—Irinotecan—pancreatic cancer	0.000378	0.00125	CcSEcCtD
Lithium—Arrhythmia—Epirubicin—pancreatic cancer	0.000373	0.00124	CcSEcCtD
Lithium—Alopecia—Epirubicin—pancreatic cancer	0.000369	0.00122	CcSEcCtD
Lithium—Nausea—Gemcitabine—pancreatic cancer	0.000368	0.00122	CcSEcCtD
Lithium—Feeling abnormal—Docetaxel—pancreatic cancer	0.000362	0.0012	CcSEcCtD
Lithium—Nausea—Fluorouracil—pancreatic cancer	0.000362	0.0012	CcSEcCtD
Lithium—Tinnitus—Doxorubicin—pancreatic cancer	0.00036	0.00119	CcSEcCtD
Lithium—Gastrointestinal pain—Docetaxel—pancreatic cancer	0.00036	0.00119	CcSEcCtD
Lithium—Flatulence—Epirubicin—pancreatic cancer	0.000358	0.00119	CcSEcCtD
Lithium—Dysgeusia—Epirubicin—pancreatic cancer	0.000356	0.00118	CcSEcCtD
Lithium—Abdominal pain—Docetaxel—pancreatic cancer	0.000348	0.00115	CcSEcCtD
Lithium—Body temperature increased—Docetaxel—pancreatic cancer	0.000348	0.00115	CcSEcCtD
Lithium—Arrhythmia—Doxorubicin—pancreatic cancer	0.000345	0.00114	CcSEcCtD
Lithium—Vision blurred—Epirubicin—pancreatic cancer	0.000343	0.00113	CcSEcCtD
Lithium—Alopecia—Doxorubicin—pancreatic cancer	0.000341	0.00113	CcSEcCtD
Lithium—Agitation—Epirubicin—pancreatic cancer	0.000334	0.00111	CcSEcCtD
Lithium—Flatulence—Doxorubicin—pancreatic cancer	0.000331	0.0011	CcSEcCtD
Lithium—Dysgeusia—Doxorubicin—pancreatic cancer	0.000329	0.00109	CcSEcCtD
Lithium—Vertigo—Epirubicin—pancreatic cancer	0.000327	0.00108	CcSEcCtD
Lithium—Syncope—Epirubicin—pancreatic cancer	0.000326	0.00108	CcSEcCtD
Lithium—Loss of consciousness—Epirubicin—pancreatic cancer	0.00032	0.00106	CcSEcCtD
Lithium—Vision blurred—Doxorubicin—pancreatic cancer	0.000317	0.00105	CcSEcCtD
Lithium—Asthenia—Docetaxel—pancreatic cancer	0.000316	0.00104	CcSEcCtD
Lithium—Convulsion—Epirubicin—pancreatic cancer	0.000315	0.00104	CcSEcCtD
Lithium—Arthralgia—Epirubicin—pancreatic cancer	0.000309	0.00102	CcSEcCtD
Lithium—Agitation—Doxorubicin—pancreatic cancer	0.000309	0.00102	CcSEcCtD
Lithium—Discomfort—Epirubicin—pancreatic cancer	0.000306	0.00101	CcSEcCtD
Lithium—Dry mouth—Epirubicin—pancreatic cancer	0.000303	0.001	CcSEcCtD
Lithium—Vertigo—Doxorubicin—pancreatic cancer	0.000302	0.001	CcSEcCtD
Lithium—Syncope—Doxorubicin—pancreatic cancer	0.000302	0.000999	CcSEcCtD
Lithium—Diarrhoea—Docetaxel—pancreatic cancer	0.000301	0.000997	CcSEcCtD
Lithium—Confusional state—Epirubicin—pancreatic cancer	0.000299	0.000991	CcSEcCtD
Lithium—Oedema—Epirubicin—pancreatic cancer	0.000297	0.000982	CcSEcCtD
Lithium—Loss of consciousness—Doxorubicin—pancreatic cancer	0.000296	0.000979	CcSEcCtD
Lithium—Shock—Epirubicin—pancreatic cancer	0.000292	0.000967	CcSEcCtD
Lithium—Convulsion—Doxorubicin—pancreatic cancer	0.000291	0.000965	CcSEcCtD
Lithium—Dizziness—Docetaxel—pancreatic cancer	0.000291	0.000963	CcSEcCtD
Lithium—Arthralgia—Doxorubicin—pancreatic cancer	0.000286	0.000948	CcSEcCtD
Lithium—Discomfort—Doxorubicin—pancreatic cancer	0.000283	0.000937	CcSEcCtD
Lithium—Anorexia—Epirubicin—pancreatic cancer	0.000283	0.000936	CcSEcCtD
Lithium—Dry mouth—Doxorubicin—pancreatic cancer	0.00028	0.000927	CcSEcCtD
Lithium—Vomiting—Docetaxel—pancreatic cancer	0.00028	0.000926	CcSEcCtD
Lithium—Rash—Docetaxel—pancreatic cancer	0.000277	0.000918	CcSEcCtD
Lithium—Hypotension—Epirubicin—pancreatic cancer	0.000277	0.000918	CcSEcCtD
Lithium—Dermatitis—Docetaxel—pancreatic cancer	0.000277	0.000917	CcSEcCtD
Lithium—Confusional state—Doxorubicin—pancreatic cancer	0.000277	0.000917	CcSEcCtD
Lithium—Headache—Docetaxel—pancreatic cancer	0.000276	0.000912	CcSEcCtD
Lithium—Oedema—Doxorubicin—pancreatic cancer	0.000275	0.000909	CcSEcCtD
Lithium—Musculoskeletal discomfort—Epirubicin—pancreatic cancer	0.00027	0.000895	CcSEcCtD
Lithium—Shock—Doxorubicin—pancreatic cancer	0.00027	0.000894	CcSEcCtD
Lithium—Somnolence—Epirubicin—pancreatic cancer	0.000264	0.000873	CcSEcCtD
Lithium—Anorexia—Doxorubicin—pancreatic cancer	0.000262	0.000866	CcSEcCtD
Lithium—Nausea—Docetaxel—pancreatic cancer	0.000261	0.000865	CcSEcCtD
Lithium—Dyspepsia—Epirubicin—pancreatic cancer	0.000261	0.000865	CcSEcCtD
Lithium—Decreased appetite—Epirubicin—pancreatic cancer	0.000258	0.000854	CcSEcCtD
Lithium—Hypotension—Doxorubicin—pancreatic cancer	0.000257	0.000849	CcSEcCtD
Lithium—Fatigue—Epirubicin—pancreatic cancer	0.000256	0.000847	CcSEcCtD
Lithium—Musculoskeletal discomfort—Doxorubicin—pancreatic cancer	0.00025	0.000828	CcSEcCtD
Lithium—Feeling abnormal—Epirubicin—pancreatic cancer	0.000244	0.00081	CcSEcCtD
Lithium—Somnolence—Doxorubicin—pancreatic cancer	0.000244	0.000808	CcSEcCtD
Lithium—Gastrointestinal pain—Epirubicin—pancreatic cancer	0.000243	0.000803	CcSEcCtD
Lithium—Dyspepsia—Doxorubicin—pancreatic cancer	0.000242	0.0008	CcSEcCtD
Lithium—Decreased appetite—Doxorubicin—pancreatic cancer	0.000239	0.00079	CcSEcCtD
Lithium—Fatigue—Doxorubicin—pancreatic cancer	0.000237	0.000784	CcSEcCtD
Lithium—Abdominal pain—Epirubicin—pancreatic cancer	0.000235	0.000777	CcSEcCtD
Lithium—Body temperature increased—Epirubicin—pancreatic cancer	0.000235	0.000777	CcSEcCtD
Lithium—Feeling abnormal—Doxorubicin—pancreatic cancer	0.000226	0.000749	CcSEcCtD
Lithium—Gastrointestinal pain—Doxorubicin—pancreatic cancer	0.000224	0.000743	CcSEcCtD
Lithium—Abdominal pain—Doxorubicin—pancreatic cancer	0.000217	0.000719	CcSEcCtD
Lithium—Body temperature increased—Doxorubicin—pancreatic cancer	0.000217	0.000719	CcSEcCtD
Lithium—Asthenia—Epirubicin—pancreatic cancer	0.000213	0.000705	CcSEcCtD
Lithium—Diarrhoea—Epirubicin—pancreatic cancer	0.000203	0.000672	CcSEcCtD
Lithium—Asthenia—Doxorubicin—pancreatic cancer	0.000197	0.000652	CcSEcCtD
Lithium—Dizziness—Epirubicin—pancreatic cancer	0.000196	0.00065	CcSEcCtD
Lithium—Vomiting—Epirubicin—pancreatic cancer	0.000189	0.000625	CcSEcCtD
Lithium—Diarrhoea—Doxorubicin—pancreatic cancer	0.000188	0.000622	CcSEcCtD
Lithium—Rash—Epirubicin—pancreatic cancer	0.000187	0.000619	CcSEcCtD
Lithium—Dermatitis—Epirubicin—pancreatic cancer	0.000187	0.000619	CcSEcCtD
Lithium—Headache—Epirubicin—pancreatic cancer	0.000186	0.000615	CcSEcCtD
Lithium—Dizziness—Doxorubicin—pancreatic cancer	0.000182	0.000601	CcSEcCtD
Lithium—Nausea—Epirubicin—pancreatic cancer	0.000176	0.000584	CcSEcCtD
Lithium—Vomiting—Doxorubicin—pancreatic cancer	0.000175	0.000578	CcSEcCtD
Lithium—Rash—Doxorubicin—pancreatic cancer	0.000173	0.000573	CcSEcCtD
Lithium—Dermatitis—Doxorubicin—pancreatic cancer	0.000173	0.000573	CcSEcCtD
Lithium—Headache—Doxorubicin—pancreatic cancer	0.000172	0.000569	CcSEcCtD
Lithium—Nausea—Doxorubicin—pancreatic cancer	0.000163	0.00054	CcSEcCtD
Lithium—GSK3B—Axon guidance—SRC—pancreatic cancer	0.000124	0.000201	CbGpPWpGaD
Lithium—GSK3B—Signaling by EGFR—AKT1—pancreatic cancer	0.000124	0.000201	CbGpPWpGaD
Lithium—GSK3B—Signaling by EGFR in Cancer—AKT1—pancreatic cancer	0.000123	0.000199	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—SST—pancreatic cancer	0.000123	0.000198	CbGpPWpGaD
Lithium—GSK3B—Signaling by PDGF—AKT1—pancreatic cancer	0.000122	0.000198	CbGpPWpGaD
Lithium—GSK3B—Adaptive Immune System—EGF—pancreatic cancer	0.000121	0.000196	CbGpPWpGaD
Lithium—GSK3B—Axon guidance—VEGFA—pancreatic cancer	0.000121	0.000196	CbGpPWpGaD
Lithium—GSK3B—Disease—CD44—pancreatic cancer	0.00012	0.000195	CbGpPWpGaD
Lithium—GSK3B—Signaling by NGF—EGFR—pancreatic cancer	0.00012	0.000194	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—JAG1—pancreatic cancer	0.00012	0.000194	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—CCK—pancreatic cancer	0.00012	0.000194	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—NOTCH3—pancreatic cancer	0.000119	0.000193	CbGpPWpGaD
Lithium—GSK3B—Disease—HSPA1A—pancreatic cancer	0.000119	0.000193	CbGpPWpGaD
Lithium—GSK3B—Axon guidance—NRAS—pancreatic cancer	0.000119	0.000193	CbGpPWpGaD
Lithium—GSK3B—Focal Adhesion—AKT1—pancreatic cancer	0.000118	0.000191	CbGpPWpGaD
Lithium—GSK3B—Immune System—IFNA2—pancreatic cancer	0.000117	0.00019	CbGpPWpGaD
Lithium—GSK3A—Innate Immune System—CTNNB1—pancreatic cancer	0.000117	0.000189	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—CNR2—pancreatic cancer	0.000116	0.000189	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—GLP1R—pancreatic cancer	0.000116	0.000189	CbGpPWpGaD
Lithium—GSK3B—B Cell Activation—AKT1—pancreatic cancer	0.000116	0.000187	CbGpPWpGaD
Lithium—GSK3A—Signaling by NGF—AKT1—pancreatic cancer	0.000115	0.000187	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—CCKAR—pancreatic cancer	0.000115	0.000186	CbGpPWpGaD
Lithium—GSK3A—Immune System—BCL2L1—pancreatic cancer	0.000114	0.000185	CbGpPWpGaD
Lithium—GSK3A—Innate Immune System—PTEN—pancreatic cancer	0.000114	0.000185	CbGpPWpGaD
Lithium—GSK3A—Immune System—TSC2—pancreatic cancer	0.000114	0.000184	CbGpPWpGaD
Lithium—GSK3B—Signaling by NGF—KRAS—pancreatic cancer	0.000113	0.000184	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—CNR1—pancreatic cancer	0.000113	0.000183	CbGpPWpGaD
Lithium—GSK3B—Signaling by Wnt—MYC—pancreatic cancer	0.000113	0.000183	CbGpPWpGaD
Lithium—GSK3B—Adaptive Immune System—CDH1—pancreatic cancer	0.000112	0.000182	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—PIK3CD—pancreatic cancer	0.000112	0.000181	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—JAG2—pancreatic cancer	0.000111	0.00018	CbGpPWpGaD
Lithium—GSK3A—Metabolism of proteins—CXCL8—pancreatic cancer	0.000111	0.000179	CbGpPWpGaD
Lithium—GSK3B—NGF signalling via TRKA from the plasma membrane—AKT1—pancreatic cancer	0.000111	0.000179	CbGpPWpGaD
Lithium—GSK3A—Disease—TERT—pancreatic cancer	0.00011	0.000178	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—MEN1—pancreatic cancer	0.00011	0.000177	CbGpPWpGaD
Lithium—GSK3A—Adaptive Immune System—PTEN—pancreatic cancer	0.000109	0.000177	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—GCG—pancreatic cancer	0.000109	0.000177	CbGpPWpGaD
Lithium—GSK3B—Axon guidance—EGFR—pancreatic cancer	0.000109	0.000176	CbGpPWpGaD
Lithium—IMPA2—Metabolism—PIK3CA—pancreatic cancer	0.000108	0.000175	CbGpPWpGaD
Lithium—GSK3B—Cellular responses to stress—TP53—pancreatic cancer	0.000107	0.000174	CbGpPWpGaD
Lithium—GSK3B—Adaptive Immune System—PIK3CD—pancreatic cancer	0.000107	0.000174	CbGpPWpGaD
Lithium—GSK3B—TCF dependent signaling in response to WNT—AKT1—pancreatic cancer	0.000106	0.000171	CbGpPWpGaD
Lithium—GSK3A—Innate Immune System—SRC—pancreatic cancer	0.000106	0.000171	CbGpPWpGaD
Lithium—GSK3A—Disease—HIF1A—pancreatic cancer	0.000105	0.00017	CbGpPWpGaD
Lithium—GSK3A—Disease—TSC2—pancreatic cancer	0.000105	0.00017	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—SHH—pancreatic cancer	0.000104	0.000169	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—AGTR1—pancreatic cancer	0.000104	0.000169	CbGpPWpGaD
Lithium—GSK3B—Signaling by NGF—PIK3CA—pancreatic cancer	0.000104	0.000169	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—NOTCH4—pancreatic cancer	0.000104	0.000168	CbGpPWpGaD
Lithium—GSK3A—Immune System—NFKBIA—pancreatic cancer	0.000104	0.000168	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—IAPP—pancreatic cancer	0.000103	0.000167	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—STK11—pancreatic cancer	0.000103	0.000166	CbGpPWpGaD
Lithium—GSK3B—Axon guidance—KRAS—pancreatic cancer	0.000103	0.000166	CbGpPWpGaD
Lithium—GSK3A—Disease—APOE—pancreatic cancer	0.000103	0.000166	CbGpPWpGaD
Lithium—GSK3B—RNF mutants show enhanced WNT signaling and proliferation—AKT1—pancreatic cancer	0.000102	0.000166	CbGpPWpGaD
Lithium—GSK3A—Metabolism of proteins—CTNNB1—pancreatic cancer	0.000102	0.000166	CbGpPWpGaD
Lithium—GSK3A—Innate Immune System—NRAS—pancreatic cancer	0.000102	0.000165	CbGpPWpGaD
Lithium—GSK3A—Adaptive Immune System—SRC—pancreatic cancer	0.000102	0.000164	CbGpPWpGaD
Lithium—GSK3A—Immune System—EGF—pancreatic cancer	9.91e-05	0.000161	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—PTCH1—pancreatic cancer	9.9e-05	0.00016	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—PTHLH—pancreatic cancer	9.9e-05	0.00016	CbGpPWpGaD
Lithium—GSK3B—Developmental Biology—CTNNB1—pancreatic cancer	9.79e-05	0.000159	CbGpPWpGaD
Lithium—GSK3A—Adaptive Immune System—NRAS—pancreatic cancer	9.77e-05	0.000158	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—PIK3CB—pancreatic cancer	9.75e-05	0.000158	CbGpPWpGaD
Lithium—GSK3B—Signaling by NGF—HRAS—pancreatic cancer	9.64e-05	0.000156	CbGpPWpGaD
Lithium—IMPA1—Metabolism—PIK3CA—pancreatic cancer	9.62e-05	0.000156	CbGpPWpGaD
Lithium—GSK3B—Developmental Biology—MMP9—pancreatic cancer	9.6e-05	0.000155	CbGpPWpGaD
Lithium—GSK3B—Signaling by WNT in cancer—AKT1—pancreatic cancer	9.51e-05	0.000154	CbGpPWpGaD
Lithium—GSK3B—Disease—SMAD4—pancreatic cancer	9.49e-05	0.000154	CbGpPWpGaD
Lithium—GSK3A—Disease—NOTCH1—pancreatic cancer	9.47e-05	0.000153	CbGpPWpGaD
Lithium—GSK3B—Adaptive Immune System—PIK3CB—pancreatic cancer	9.36e-05	0.000152	CbGpPWpGaD
Lithium—GSK3B—Disease—HES1—pancreatic cancer	9.27e-05	0.00015	CbGpPWpGaD
Lithium—GSK3A—Innate Immune System—EGFR—pancreatic cancer	9.27e-05	0.00015	CbGpPWpGaD
Lithium—GSK3A—Immune System—CDH1—pancreatic cancer	9.23e-05	0.000149	CbGpPWpGaD
Lithium—GSK3A—Disease—EGF—pancreatic cancer	9.15e-05	0.000148	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—SST—pancreatic cancer	9.06e-05	0.000147	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—SMAD4—pancreatic cancer	9e-05	0.000146	CbGpPWpGaD
Lithium—GSK3A—Adaptive Immune System—EGFR—pancreatic cancer	8.9e-05	0.000144	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—JAG1—pancreatic cancer	8.86e-05	0.000144	CbGpPWpGaD
Lithium—GSK3B—Developmental Biology—SRC—pancreatic cancer	8.85e-05	0.000143	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—NOTCH3—pancreatic cancer	8.83e-05	0.000143	CbGpPWpGaD
Lithium—IMPA2—Metabolism—AKT1—pancreatic cancer	8.82e-05	0.000143	CbGpPWpGaD
Lithium—GSK3A—Immune System—PIK3CD—pancreatic cancer	8.82e-05	0.000143	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—HES1—pancreatic cancer	8.78e-05	0.000142	CbGpPWpGaD
Lithium—GSK3A—Innate Immune System—KRAS—pancreatic cancer	8.76e-05	0.000142	CbGpPWpGaD
Lithium—GSK3B—Axon guidance—HRAS—pancreatic cancer	8.73e-05	0.000141	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—CTNNB1—pancreatic cancer	8.65e-05	0.00014	CbGpPWpGaD
Lithium—GSK3B—Developmental Biology—VEGFA—pancreatic cancer	8.62e-05	0.00014	CbGpPWpGaD
Lithium—GSK3B—Developmental Biology—STAT3—pancreatic cancer	8.53e-05	0.000138	CbGpPWpGaD
Lithium—GSK3B—Signaling by NGF—AKT1—pancreatic cancer	8.51e-05	0.000138	CbGpPWpGaD
Lithium—GSK3B—Developmental Biology—NRAS—pancreatic cancer	8.51e-05	0.000138	CbGpPWpGaD
Lithium—GSK3B—Immune System—BCL2L1—pancreatic cancer	8.44e-05	0.000137	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—PTEN—pancreatic cancer	8.43e-05	0.000136	CbGpPWpGaD
Lithium—GSK3A—Adaptive Immune System—KRAS—pancreatic cancer	8.41e-05	0.000136	CbGpPWpGaD
Lithium—GSK3B—Immune System—TSC2—pancreatic cancer	8.39e-05	0.000136	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—CNR1—pancreatic cancer	8.36e-05	0.000135	CbGpPWpGaD
Lithium—GSK3A—Disease—PIK3CD—pancreatic cancer	8.14e-05	0.000132	CbGpPWpGaD
Lithium—GSK3B—Disease—TERT—pancreatic cancer	8.12e-05	0.000132	CbGpPWpGaD
Lithium—GSK3B—Adaptive Immune System—PTEN—pancreatic cancer	8.09e-05	0.000131	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—GCG—pancreatic cancer	8.07e-05	0.000131	CbGpPWpGaD
Lithium—GSK3A—Innate Immune System—PIK3CA—pancreatic cancer	8.04e-05	0.00013	CbGpPWpGaD
Lithium—GSK3B—Developmental Biology—TGFB1—pancreatic cancer	7.91e-05	0.000128	CbGpPWpGaD
Lithium—IMPA1—Metabolism—AKT1—pancreatic cancer	7.86e-05	0.000127	CbGpPWpGaD
Lithium—GSK3B—Signaling by Wnt—AKT1—pancreatic cancer	7.84e-05	0.000127	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—SRC—pancreatic cancer	7.81e-05	0.000127	CbGpPWpGaD
Lithium—GSK3B—Disease—HIF1A—pancreatic cancer	7.77e-05	0.000126	CbGpPWpGaD
Lithium—GSK3B—Developmental Biology—EGFR—pancreatic cancer	7.76e-05	0.000126	CbGpPWpGaD
Lithium—GSK3B—Disease—TSC2—pancreatic cancer	7.75e-05	0.000125	CbGpPWpGaD
Lithium—GSK3A—Adaptive Immune System—PIK3CA—pancreatic cancer	7.72e-05	0.000125	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—AGTR1—pancreatic cancer	7.7e-05	0.000125	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—TERT—pancreatic cancer	7.7e-05	0.000125	CbGpPWpGaD
Lithium—GSK3A—Immune System—PIK3CB—pancreatic cancer	7.69e-05	0.000124	CbGpPWpGaD
Lithium—GSK3B—Immune System—NFKBIA—pancreatic cancer	7.65e-05	0.000124	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—STK11—pancreatic cancer	7.59e-05	0.000123	CbGpPWpGaD
Lithium—GSK3B—Disease—APOE—pancreatic cancer	7.58e-05	0.000123	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—NRAS—pancreatic cancer	7.52e-05	0.000122	CbGpPWpGaD
Lithium—GSK3B—Adaptive Immune System—SRC—pancreatic cancer	7.5e-05	0.000122	CbGpPWpGaD
Lithium—GSK3A—Innate Immune System—HRAS—pancreatic cancer	7.44e-05	0.000121	CbGpPWpGaD
Lithium—GSK3B—Developmental Biology—TNF—pancreatic cancer	7.39e-05	0.00012	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—HIF1A—pancreatic cancer	7.36e-05	0.000119	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—TSC2—pancreatic cancer	7.34e-05	0.000119	CbGpPWpGaD
Lithium—GSK3B—Immune System—EGF—pancreatic cancer	7.33e-05	0.000119	CbGpPWpGaD
Lithium—GSK3B—Developmental Biology—KRAS—pancreatic cancer	7.33e-05	0.000119	CbGpPWpGaD
Lithium—GSK3B—Adaptive Immune System—NRAS—pancreatic cancer	7.22e-05	0.000117	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—APOE—pancreatic cancer	7.19e-05	0.000116	CbGpPWpGaD
Lithium—GSK3A—Adaptive Immune System—HRAS—pancreatic cancer	7.15e-05	0.000116	CbGpPWpGaD
Lithium—GSK3A—Disease—PIK3CB—pancreatic cancer	7.1e-05	0.000115	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—KDR—pancreatic cancer	7.04e-05	0.000114	CbGpPWpGaD
Lithium—GSK3A—Disease—PTGS2—pancreatic cancer	7.03e-05	0.000114	CbGpPWpGaD
Lithium—GSK3B—Disease—NOTCH1—pancreatic cancer	7e-05	0.000113	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—EGFR—pancreatic cancer	6.85e-05	0.000111	CbGpPWpGaD
Lithium—GSK3B—Immune System—CDH1—pancreatic cancer	6.82e-05	0.00011	CbGpPWpGaD
Lithium—GSK3A—Immune System—CTNNB1—pancreatic cancer	6.81e-05	0.00011	CbGpPWpGaD
Lithium—GSK3B—Disease—EGF—pancreatic cancer	6.76e-05	0.00011	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—NFKBIA—pancreatic cancer	6.7e-05	0.000108	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—SMAD4—pancreatic cancer	6.65e-05	0.000108	CbGpPWpGaD
Lithium—GSK3A—Immune System—PTEN—pancreatic cancer	6.64e-05	0.000108	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—NOTCH1—pancreatic cancer	6.63e-05	0.000107	CbGpPWpGaD
Lithium—GSK3B—Adaptive Immune System—EGFR—pancreatic cancer	6.58e-05	0.000107	CbGpPWpGaD
Lithium—GSK3A—Innate Immune System—AKT1—pancreatic cancer	6.57e-05	0.000106	CbGpPWpGaD
Lithium—GSK3B—Immune System—PIK3CD—pancreatic cancer	6.52e-05	0.000106	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—HES1—pancreatic cancer	6.49e-05	0.000105	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—PIK3CG—pancreatic cancer	6.49e-05	0.000105	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—KRAS—pancreatic cancer	6.47e-05	0.000105	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—EGF—pancreatic cancer	6.41e-05	0.000104	CbGpPWpGaD
Lithium—GSK3A—Adaptive Immune System—AKT1—pancreatic cancer	6.31e-05	0.000102	CbGpPWpGaD
Lithium—GSK3A—Disease—CTNNB1—pancreatic cancer	6.29e-05	0.000102	CbGpPWpGaD
Lithium—GSK3B—Developmental Biology—HRAS—pancreatic cancer	6.23e-05	0.000101	CbGpPWpGaD
Lithium—GSK3B—Adaptive Immune System—KRAS—pancreatic cancer	6.21e-05	0.000101	CbGpPWpGaD
Lithium—GSK3A—Immune System—SRC—pancreatic cancer	6.16e-05	9.97e-05	CbGpPWpGaD
Lithium—GSK3A—Disease—PTEN—pancreatic cancer	6.13e-05	9.93e-05	CbGpPWpGaD
Lithium—GSK3B—Disease—PIK3CD—pancreatic cancer	6.02e-05	9.74e-05	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—PIK3CA—pancreatic cancer	5.94e-05	9.63e-05	CbGpPWpGaD
Lithium—GSK3A—Immune System—STAT3—pancreatic cancer	5.94e-05	9.62e-05	CbGpPWpGaD
Lithium—GSK3A—Immune System—NRAS—pancreatic cancer	5.93e-05	9.6e-05	CbGpPWpGaD
Lithium—GSK3B—Adaptive Immune System—PIK3CA—pancreatic cancer	5.71e-05	9.24e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—PIK3CD—pancreatic cancer	5.7e-05	9.23e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—TERT—pancreatic cancer	5.69e-05	9.21e-05	CbGpPWpGaD
Lithium—GSK3A—Disease—SRC—pancreatic cancer	5.69e-05	9.21e-05	CbGpPWpGaD
Lithium—GSK3B—Immune System—PIK3CB—pancreatic cancer	5.68e-05	9.2e-05	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—HRAS—pancreatic cancer	5.5e-05	8.91e-05	CbGpPWpGaD
Lithium—GSK3B—Developmental Biology—AKT1—pancreatic cancer	5.5e-05	8.9e-05	CbGpPWpGaD
Lithium—GSK3A—Disease—STAT3—pancreatic cancer	5.48e-05	8.88e-05	CbGpPWpGaD
Lithium—GSK3A—Disease—NRAS—pancreatic cancer	5.47e-05	8.86e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—HIF1A—pancreatic cancer	5.44e-05	8.81e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—TSC2—pancreatic cancer	5.43e-05	8.79e-05	CbGpPWpGaD
Lithium—GSK3A—Immune System—EGFR—pancreatic cancer	5.4e-05	8.74e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—APOE—pancreatic cancer	5.31e-05	8.6e-05	CbGpPWpGaD
Lithium—GSK3B—Adaptive Immune System—HRAS—pancreatic cancer	5.28e-05	8.55e-05	CbGpPWpGaD
Lithium—GSK3B—Disease—PIK3CB—pancreatic cancer	5.24e-05	8.49e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—KDR—pancreatic cancer	5.2e-05	8.42e-05	CbGpPWpGaD
Lithium—GSK3B—Disease—PTGS2—pancreatic cancer	5.2e-05	8.41e-05	CbGpPWpGaD
Lithium—GSK3A—Immune System—KRAS—pancreatic cancer	5.1e-05	8.26e-05	CbGpPWpGaD
Lithium—GSK3A—Disease—MYC—pancreatic cancer	5.1e-05	8.25e-05	CbGpPWpGaD
Lithium—GSK3A—Disease—TGFB1—pancreatic cancer	5.08e-05	8.23e-05	CbGpPWpGaD
Lithium—GSK3B—Immune System—CTNNB1—pancreatic cancer	5.04e-05	8.15e-05	CbGpPWpGaD
Lithium—GSK3A—Disease—EGFR—pancreatic cancer	4.98e-05	8.07e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—PIK3CB—pancreatic cancer	4.97e-05	8.05e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—NFKBIA—pancreatic cancer	4.95e-05	8.01e-05	CbGpPWpGaD
Lithium—GSK3B—Immune System—PTEN—pancreatic cancer	4.91e-05	7.95e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—NOTCH1—pancreatic cancer	4.9e-05	7.94e-05	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—AKT1—pancreatic cancer	4.86e-05	7.86e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—PIK3CG—pancreatic cancer	4.79e-05	7.76e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—CXCL8—pancreatic cancer	4.78e-05	7.73e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—EGF—pancreatic cancer	4.74e-05	7.67e-05	CbGpPWpGaD
Lithium—GSK3A—Disease—KRAS—pancreatic cancer	4.71e-05	7.62e-05	CbGpPWpGaD
Lithium—GSK3A—Immune System—PIK3CA—pancreatic cancer	4.69e-05	7.59e-05	CbGpPWpGaD
Lithium—GSK3B—Adaptive Immune System—AKT1—pancreatic cancer	4.66e-05	7.55e-05	CbGpPWpGaD
Lithium—GSK3B—Disease—CTNNB1—pancreatic cancer	4.65e-05	7.53e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—CASP3—pancreatic cancer	4.57e-05	7.4e-05	CbGpPWpGaD
Lithium—GSK3B—Immune System—SRC—pancreatic cancer	4.55e-05	7.37e-05	CbGpPWpGaD
Lithium—GSK3B—Disease—PTEN—pancreatic cancer	4.53e-05	7.34e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—CCND1—pancreatic cancer	4.45e-05	7.2e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—CTNNB1—pancreatic cancer	4.41e-05	7.13e-05	CbGpPWpGaD
Lithium—GSK3B—Immune System—STAT3—pancreatic cancer	4.39e-05	7.11e-05	CbGpPWpGaD
Lithium—GSK3B—Immune System—NRAS—pancreatic cancer	4.38e-05	7.09e-05	CbGpPWpGaD
Lithium—GSK3A—Immune System—HRAS—pancreatic cancer	4.33e-05	7.02e-05	CbGpPWpGaD
Lithium—GSK3A—Disease—PIK3CA—pancreatic cancer	4.33e-05	7.01e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—MMP9—pancreatic cancer	4.32e-05	6.99e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—PTEN—pancreatic cancer	4.29e-05	6.95e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—PIK3CD—pancreatic cancer	4.21e-05	6.82e-05	CbGpPWpGaD
Lithium—GSK3B—Disease—SRC—pancreatic cancer	4.2e-05	6.8e-05	CbGpPWpGaD
Lithium—GSK3B—Disease—STAT3—pancreatic cancer	4.05e-05	6.56e-05	CbGpPWpGaD
Lithium—GSK3B—Disease—NRAS—pancreatic cancer	4.04e-05	6.55e-05	CbGpPWpGaD
Lithium—GSK3A—Disease—HRAS—pancreatic cancer	4e-05	6.48e-05	CbGpPWpGaD
Lithium—GSK3B—Immune System—EGFR—pancreatic cancer	3.99e-05	6.46e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—SRC—pancreatic cancer	3.98e-05	6.45e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—VEGFA—pancreatic cancer	3.88e-05	6.28e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—STAT3—pancreatic cancer	3.84e-05	6.22e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—NRAS—pancreatic cancer	3.83e-05	6.2e-05	CbGpPWpGaD
Lithium—GSK3A—Immune System—AKT1—pancreatic cancer	3.83e-05	6.2e-05	CbGpPWpGaD
Lithium—GSK3B—Immune System—KRAS—pancreatic cancer	3.77e-05	6.1e-05	CbGpPWpGaD
Lithium—GSK3B—Disease—MYC—pancreatic cancer	3.77e-05	6.1e-05	CbGpPWpGaD
Lithium—GSK3B—Disease—TGFB1—pancreatic cancer	3.76e-05	6.08e-05	CbGpPWpGaD
Lithium—GSK3B—Disease—EGFR—pancreatic cancer	3.68e-05	5.96e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—PIK3CB—pancreatic cancer	3.67e-05	5.95e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—MYC—pancreatic cancer	3.57e-05	5.78e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—TGFB1—pancreatic cancer	3.56e-05	5.76e-05	CbGpPWpGaD
Lithium—GSK3A—Disease—AKT1—pancreatic cancer	3.53e-05	5.72e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—CXCL8—pancreatic cancer	3.53e-05	5.71e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—EGFR—pancreatic cancer	3.49e-05	5.65e-05	CbGpPWpGaD
Lithium—GSK3B—Disease—KRAS—pancreatic cancer	3.48e-05	5.63e-05	CbGpPWpGaD
Lithium—GSK3B—Immune System—PIK3CA—pancreatic cancer	3.46e-05	5.61e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—CASP3—pancreatic cancer	3.38e-05	5.47e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—KRAS—pancreatic cancer	3.3e-05	5.34e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—CCND1—pancreatic cancer	3.29e-05	5.32e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—CTNNB1—pancreatic cancer	3.26e-05	5.27e-05	CbGpPWpGaD
Lithium—GSK3B—Immune System—HRAS—pancreatic cancer	3.2e-05	5.19e-05	CbGpPWpGaD
Lithium—GSK3B—Disease—PIK3CA—pancreatic cancer	3.2e-05	5.18e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—MMP9—pancreatic cancer	3.19e-05	5.17e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—PTEN—pancreatic cancer	3.17e-05	5.14e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—PIK3CA—pancreatic cancer	3.03e-05	4.91e-05	CbGpPWpGaD
Lithium—GSK3B—Disease—HRAS—pancreatic cancer	2.96e-05	4.79e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—SRC—pancreatic cancer	2.94e-05	4.77e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—TP53—pancreatic cancer	2.93e-05	4.75e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—VEGFA—pancreatic cancer	2.87e-05	4.64e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—STAT3—pancreatic cancer	2.84e-05	4.6e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—NRAS—pancreatic cancer	2.83e-05	4.58e-05	CbGpPWpGaD
Lithium—GSK3B—Immune System—AKT1—pancreatic cancer	2.83e-05	4.58e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—HRAS—pancreatic cancer	2.8e-05	4.54e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—MYC—pancreatic cancer	2.64e-05	4.27e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—TGFB1—pancreatic cancer	2.63e-05	4.26e-05	CbGpPWpGaD
Lithium—GSK3B—Disease—AKT1—pancreatic cancer	2.61e-05	4.23e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—EGFR—pancreatic cancer	2.58e-05	4.18e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—AKT1—pancreatic cancer	2.47e-05	4.01e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—KRAS—pancreatic cancer	2.44e-05	3.95e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—PIK3CA—pancreatic cancer	2.24e-05	3.62e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—TP53—pancreatic cancer	2.17e-05	3.51e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—HRAS—pancreatic cancer	2.07e-05	3.35e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—AKT1—pancreatic cancer	1.83e-05	2.96e-05	CbGpPWpGaD
